the UCB acquires Us biopharmaceutical company, Ra Pharmaceuticals and over. One of the pharmaceutical company on Thursday announced. UCB will pay 2 billion euros for the Ra Pharma.

in The U.s. the company is founded in 2008 and is developing treatments for the diseases that the immune system is at risk. The most important thing a candidate drug that has the Ra Pharma is developing zilucoplan: an option for the treatment of myasthenia gravis, a serious muscular disorder world-wide to 200,000 people have been affected. Zilucoplan is in phase 3, the final phase of development of a candidate drug prior to the approval of the authorities, in order to be introduced to the market.

the UCB will pay the 48 dollars, cash per share is at Ra Pharmaceuticals, a premium of 93 per cent on the average share price for the last 30 days. UCB will pay a total of € 2.2 billion for the company in the Us. Taking into account all the cash in the biopharmaceutical company, this boils down to a take-over of eur 2 billion.

the boards of directors of the acquisition has already been approved. UCB hopes to have the acquisition complete by the end of the first quarter of next year.

the acquisition is The largest in the last decade for UCB. It is a Belgian pharmaceutical company also works with a form of treatment for myasthenia gravis, which is also in phase three of the development is. UCB’s CEO christophe Tellier is called Ra Pharma is an “excellent strategic addition”.

More about UCB UCB completes sale of American subsidiary to 1,23 billion-dollar, UCB, screw the profit forecast on the Bel20 index may be a recovery on Monday to continue to Drop sharply on Friday on the stock exchange, partly rubbed out